Frank J Schoenen

List of Publications by Year
in descending order

62	4,912	186265 28	123424 61
papers	citations	h-index	g-index

67	67	67	6235
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Discovery and Optimization of Pyrrolopyrimidine Derivatives as Selective Disruptors of the Perinucleolar Compartment, a Marker of Tumor Progression toward Metastasis. Journal of Medicinal Chemistry, 2022, 65, 8303-8331.	6.4	4
2	Repurposing p97 inhibitors for chemical modulation of the bacterial ClpBâ€“DnaK bichaperone system. Journal of Biological Chemistry, 2021, 296, 100079.	3.4	8
3	Activity-Based Protein Profiling Reveals That Cephalosporins Selectively Active on Non-replicating Mycobacterium tuberculosis Bind Multiple Protein Families and Spare Peptidoglycan Transpeptidases. Frontiers in Microbiology, 2020, 11, 1248.	3.5	11
4	Identification of Antimalarial Inhibitors Using Late-Stage Gametocytes in a Phenotypic Live/Dead Assay. SLAS Discovery, 2019, 24, 38-46.	2.7	5
5	Revisiting the Î²-Lactams for Tuberculosis Therapy with a Compound-Compound Synthetic Lethality Approach. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	4
6	Functional cooperativity of p97 and histone deacetylase 6 in mediating DNA repair in mantle cell lymphoma cells. Leukemia, 2019, 33, 1675-1686.	7.2	12
7	Effect of C-2 substitution on the stability of non-traditional cephalosporins in mouse plasma. Journal of Antibiotics, 2019, 72, 469-475.	2.0	0
8	Metarrestin, a perinucleolar compartment inhibitor, effectively suppresses metastasis. Science Translational Medicine, 2018, 10, .	12.4	55
9	Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle. Journal of Medicinal Chemistry, 2017, 60, 6364-6383.	6.4	12
10	Targeting p97 to Disrupt Protein Homeostasis in Cancer. Frontiers in Oncology, 2016, 6, 181.	2.8	49
11	Novel Cephalosporins Selectively Active on Nonreplicating Mycobacterium tuberculosis. Journal of Medicinal Chemistry, 2016, 59, 6027-6044.	6.4	45
12	VCP inhibitors induce endoplasmic reticulum stress, causeÂcell cycle arrest, trigger caspaseâ€mediated cell deathÂand synergistically kill ovarian cancer cells in combination with Salubrinal. Molecular Oncology, 2016, 10, 1559-1574.	4.6	69
13	A New Glucocerebrosidase Chaperone Reduces Â-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism. Journal of Neuroscience, 2016, 36, 7441-7452.	3.6	189
14	Nâ€Phenylbenzamides as Potent Inhibitors of the Mitochondrial Permeability Transition Pore. ChemMedChem, 2016, 11, 283-288.	3.2	34
15	Autophagy activation by novel inducers prevents BECN2-mediated drug tolerance to cannabinoids. Autophagy, 2016, 12, 1460-1471.	9.1	12
16	Evaluating p97 Inhibitor Analogues for Potency against p97â€“p37 and p97â€“Npl4â€“Ufd1 Complexes. ChemMedChem, 2016, 11, 953-957.	3.2	13
17	Threading the Needle: Small-Molecule Targeting of a Xenobiotic Receptor to AblateEscherichia coliPolysaccharide Capsule Expression Without Altering Antibiotic Resistance. Journal of Infectious Diseases, 2016, 213, 1330-1339.	4.0	14
18	Discovery, Synthesis, and Optimization of Diarylisoxazoleâ€3â€carboxamides as Potent Inhibitors of the Mitochondrial Permeability Transition Pore. ChemMedChem, 2015, 10, 1655-1671.	3.2	41

#	Article	IF	Citations
19	Advancing Biological Understanding and Therapeutics Discovery with Small-Molecule Probes. Cell, 2015, 161, 1252-1265.	28.9	135
20	Benzothiazole and Pyrrolone Flavivirus Inhibitors Targeting the Viral Helicase. ACS Infectious Diseases, 2015, 1, 140-148.	3.8	44
21	Potency enhancement of the Î¹-opioid receptor antagonist probe ML140 through sulfonamide constraint utilizing a tetrahydroisoquinoline motif. Bioorganic and Medicinal Chemistry, 2015, 23, 3948-3956.	3.0	7
22	Design of High-Throughput Screening Assays and Identification of a SUMO1-Specific Small Molecule Chemotype Targeting the SUMO-Interacting Motif-Binding Surface. ACS Combinatorial Science, 2015, 17, 239-246.	3.8	5
23	Simultaneously Targeting the NS3 Protease and Helicase Activities for More Effective Hepatitis C Virus Therapy. ACS Chemical Biology, 2015, 10, 1887-1896.	3.4	10
24	High-Throughput Screening, Discovery, and Optimization To Develop a Benzofuran Class of Hepatitis C Virus Inhibitors. ACS Combinatorial Science, 2015, 17, 641-652.	3.8	23
25	Evaluating p97 Inhibitor Analogues for Their Domain Selectivity and Potency against the p97â€“p47 Complex. ChemMedChem, 2015, 10, 52-56.	3.2	29
26	Identification of Potent and Selective Inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PfM18AAP) of Human Malaria via High-Throughput Screening. Journal of Biomolecular Screening, 2014, 19, 1107-1115.	2.6	15
27	Ebselen Inhibits Hepatitis C Virus NS3 Helicase Binding to Nucleic Acid and Prevents Viral Replication. ACS Chemical Biology, 2014, 9, 2393-2403.	3.4	70
28	Specific Inhibition of p97/VCP ATPase and Kinetic Analysis Demonstrate Interaction between D1 and D2 ATPase Domains. Journal of Molecular Biology, 2014, 426, 2886-2899.	4.2	103
29	Lifting the Mask: Identification of New Small Molecule Inhibitors of Uropathogenic Escherichia coli Group 2 Capsule Biogenesis. PLoS ONE, 2014, 9, e96054.	2.5	10
30	Benzylmorpholine Analogs as Selective Inhibitors of Lung Cytochrome P450 2A13 for the Chemoprevention of Lung Cancer in Tobacco Users. Pharmaceutical Research, 2013, 30, 2290-2302.	3.5	12
31	Primuline Derivatives That Mimic RNA to Stimulate Hepatitis C Virus NS3 Helicase-catalyzed ATP Hydrolysis. Journal of Biological Chemistry, 2013, 288, 19949-19957.	3.4	11
32	Structureâ€“Activity Relationship Study Reveals ML240 and ML241 as Potent and Selective Inhibitors of p97 ATPase. ChemMedChem, 2013, 8, 297-312.	3.2	119
33	Skeletal Diversification via Heteroatom Linkage Control: Preparation of Bicyclic and Spirocyclic Scaffolds from N-Substituted Homopropargyl Alcohols. Journal of Organic Chemistry, 2013, 78, 3720-3730.	3.2	24
34	Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: Development of chemical probe ML315. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 3654-3661.	2.2	43
35	Identification and analysis of hepatitis C virus NS3 helicase inhibitors using nucleic acid binding assays. Nucleic Acids Research, 2012, 40, 8607-8621.	14.5	51
36	Optimization of Potent Hepatitis C Virus NS3 Helicase Inhibitors Isolated from the Yellow Dyes Thioflavine S and Primuline. Journal of Medicinal Chemistry, 2012, 55, 3319-3330.	6.4	62

#	Article	IF	Citations
37	Fluorescent primuline derivatives inhibit hepatitis C virus NS3-catalyzed RNA unwinding, peptide hydrolysis and viral replicase formation. Antiviral Research, 2012, 96, 245-255.	4.1	18
38	Discovery of Small Molecule Kappa Opioid Receptor Agonist and Antagonist Chemotypes through a HTS and Hit Refinement Strategy. ACS Chemical Neuroscience, 2012, 3, 221-236.	3.5	42
39	Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 4834-4839.	7.1	281
40	One-Pot, Three-Component, Domino Heck-aza-Michael Approach to Libraries of Functionalized 1,1-Dioxido-1,2-benzisothiazoline-3-acetic Acids. ACS Combinatorial Science, 2009, 11, 732-738.	3.3	28
41	Three-Component Synthesis of 1,4-Diazepin-5-ones and the Construction of Î³-Turn-like Peptidomimetic Libraries. ACS Combinatorial Science, 2008, 10, 230-234.	3.3	24
42	Ionic Immobilization, Diversification, and Release: Application to the Generation of a Library of Methionine Aminopeptidase Inhibitors. ACS Combinatorial Science, 2008, 10, 185-194.	3.3	10
43	One-Step Synthesis of Oxazoline and Dihydrooxazine Libraries. ACS Combinatorial Science, 2007, 9, 473-476.	3.3	45
44	Solution-Phase Parallel Synthesis of a Library of Î”2-Pyrazolines. ACS Combinatorial Science, 2007, 9, 20-28.	3.3	24
45	Synthesis of N-Alkyl-octahydroisoquinolin-1-one-8-carboxamide Libraries Using a Tandem Dielsâ€“Alder/Acylation Sequence. ACS Combinatorial Science, 2007, 9, 1188-1192.	3.3	15
46	Arthur Suite V. 3.0 Symyx Technologies, Inc., 3100 Central Expressway, Santa Clara, CA 95051. www.symyx.com. See Web site for pricing information.. Journal of the American Chemical Society, 2006, 128, 664-665.	13.7	11
47	A Combinatorial Process for Drug Discovery. , 2005, , 231-259.		2
48	Combinatorial compound libraries for drug discovery: an ongoing challenge. Nature Reviews Drug Discovery, 2003, 2, 222-230.	46.4	203
49	Structural features and biochemical properties of TNF-Î± converting enzyme (TACE). Journal of Neuroimmunology, 1997, 72, 127-129.	2.3	106
50	Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-Î±. Nature, 1997, 385, 733-736.	27.8	1,636
51	Isotope or mass encoding of combinatorial libraries. Chemistry and Biology, 1996, 3, 679-688.	6.0	104
52	Phosphodiesterase Type IV Inhibition. Structure-Activity Relationships of 1,3-Disubstituted Pyrrolidines. Journal of Medicinal Chemistry, 1995, 38, 1505-1510.	6.4	21
53	Structure-activity relationships involving the catechol subunit of rolipram. Bioorganic and Medicinal Chemistry Letters, 1994, 4, 1855-1860.	2.2	14
54	Regulation of tumour necrosis factor-Î± processing by a metalloproteinase inhibitor. Nature, 1994, 370, 558-561.	27.8	583

#	Article	IF	Citations
55	Matrix Metalloproteinase Inhibitors Containing a [(Carboxyalkyl)amino]zinc Ligand: Modification of the P1 and P2' Residues. Journal of Medicinal Chemistry, 1994, 37, 674-688.	6.4	47
56	Matrix metalloproteinase inhibitors containing a [(carboxyalkyl)amino] zinc ligand: Modification of the P1 and P2' residues. [Erratum to document cited in CA120:238898]. Journal of Medicinal Chemistry, 1994, 37, 1546-1546.	6.4	0
57	Transannular Diels-Alder route to systems related to dynemicin A. Journal of the American Chemical Society, 1990, 112, 7410-7411.	13.7	163
58	Synthesis and crystallographic analysis of a bicyclic core related to the esperamicin/calichemicin aglycones. Tetrahedron Letters, 1989, 30, 3765-3768.	1.4	44
59	The dioxanone-to-dihydropyran Claisen rearrangement. Synthesis of C(7)-C(13) fragments of erythronolides A and B. Tetrahedron Letters, 1987, 28, 4143-4146.	1.4	25
60	An enolate claisen route to c-pyranosides. Tetrahedron, 1986, 42, 2787-2801.	1.9	50
61	The ester enolate claisen rearrangement. Synthesis of A C(1)î—‚C(6) erythronolide fragment. Tetrahedron Letters, 1986, 27, 449-452.	1.4	22
62	Polysubstituted dihydropyrans via the enolate Claisen rearrangement. A stereocontrolled route to C-pyranosides. Journal of Organic Chemistry, 1984, 49, 4320-4322.	3.2	36